Search | Clinical Trials Finder

Conditions: Pulmonary Artery Hypertension
Interventions: GB002 (seralutinib), Placebo, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more

Conditions: Blood Pressure
Interventions: Freeze-dried Blueberry Powder, Placebo; Dietary Supplement
Lead sponsor: Florida State University; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 7 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo; Drug
Lead sponsor: Othera Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more

Conditions: Uncontrolled Stage 2 Hypertension
Interventions: Renal denervation; Device
Lead sponsor: SoniVie Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 6 more

Conditions: Hypertension
Interventions: Nebivolol, Metoprolol ER (TM); Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: Iyengar yoga, Enhanced nutritional care classes; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Arterial Hypertension
Interventions: Placebo, FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml; Drug
Lead sponsor: Edda Spiekerkoetter; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Glaucoma, Primary Open Angle, Ocular Hypertension
Interventions: WB007 0.05%, WB007 0.15%, WB007 0.4%, Timolol 0.5%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: JNC 7 Stage 1 or 2 Hypertension
Interventions: Nebivolol I, Nebivolol II, Baseline Washout Phase; Drug · Other
Lead sponsor: Trinity Hypertension & Metabolic Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Carrollton, Texas

Conditions: Hypertension
Interventions: telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 100
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more

Conditions: Pulmonary Arterial Hypertension
Interventions: sapropterin dihydrochloride (6R-BH4); Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: Nebivolol, Valsartan and Hydrochlorothiazide; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 135
States / cities: Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 42
States / cities: Sun City, Arizona • Glendale, California • Inglewood, California + 38 more

Conditions: Symptomatic Neurogenic Orthostatic Hypertension, nOH
Interventions: Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Essential Hypertension
Interventions: Vasomera (PB1046), 0.9% Sodium Chloride; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 5
States / cities: Anniston, Alabama • Walnut Creek, California • Saint Paul, Minnesota + 2 more

Conditions: Hypertension, Grade 1, Hypertension Treatment, N of 1 Study Design, Hypertension
Interventions: Lisinopril, Hydrochlorothiazide; Drug
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Ocular Hypertension
Interventions: ST266 via Intranasal Delivery; Combination Product
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 20 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Essential Hypertension
Interventions: Placebo Single IV (Intravenous) Infusion, Experimental: Single IV Infusion Vasomera (PB1046); Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pulmonary Arterial Hypertension
Interventions: AIR001; Drug
Lead sponsor: Aires Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 17
States / cities: La Jolla, California • Torrance, California • Aurora, Colorado + 12 more

Conditions: Glaucoma, Open-Angle
Interventions: H-1337 Placebo, H-1337 [1], H-1337 [2], H-1337 [3]; Drug
Lead sponsor: Allysta Pharmaceutical; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Goose Creek, South Carolina

Conditions: Essential Hypertension
Interventions: Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg, Aprocitentan 50 mg, Lisinopril 20 mg, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 74
States / cities: Fort Payne, Alabama • Chandler, Arizona • Peoria, Arizona + 62 more

Conditions: Hypertension in Pregnancy
Interventions: Labetalol or Nifedipine; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 89 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

Blueberry Consumption Improves Vascular Function and Lowers Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /

A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients

The Penn Lifestyle Modification and Blood Pressure Study

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

Safety and IOP-Lowering Effects of WB007

Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

6R-BH4 Pulmonary Arterial Hypertension Study

Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

Topical Insulin for Glaucoma (TING2)

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension

Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril

Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05

H-1337 Ophthalmic Solution Phase 1/2

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project